Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07221656 · ClinicalTrials.gov registry record
Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration
A clinical trial, sponsored by Mayo Clinic.
- Not yet
- Registry status
- 20
- Enrollment target
NCT07221656: Clinical Trial study, sponsored by Mayo Clinic.
NCT07221656 is a clinical trial that has not yet begun recruiting, run by Mayo Clinic. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07221656 has not yet begun recruiting, sponsored by Mayo Clinic.
- NOT YET RECRUITING
- Registry status
- 20 participants
- Enrollment target
Study Summary
This study evaluates the median duration of therapeutic serum asparaginase activity (SAA) levels after administration of calaspargase pegol (Cal-PEG) and the potential association between peak SAA levels and duration of therapeutic levels with toxicity in pediatric patients with acute lymphoblastic leukemia or lymphoma.
Interventions
- OTHER Non-Interventional Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2027-02-01 |
| Est. Completion | 2028-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07221656
The ClinicalTrials.gov registry entry for NCT07221656 describes a study currently listed as not yet recruiting, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Non-Interventional Study is the first listed.
NCT07221656 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07221656 about?
NCT07221656 is a clinical study titled "Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration". This study evaluates the median duration of therapeutic serum asparaginase activity (SAA) levels after administration of calaspargase pegol (Cal-PEG) and the potential association between peak SAA levels and duration of therapeutic levels with toxicity in pediatric patients with acute lymphoblastic ...
What is the current status of trial NCT07221656?
This trial is currently not yet recruiting. The enrollment target is 20 participants. The study started on 2027-02-01. Estimated completion is 2028-12-31.
What interventions are being tested in trial NCT07221656?
The interventions under investigation include: Non-Interventional Study (OTHER).
Who is sponsoring clinical trial NCT07221656?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.